Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KemPharm Inc.

www.kempharm.com

Latest From Repligen Corp.

Device/Diagnostics Quarterly Deal Statistics, Q2 2016

Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.

Deals Market Intelligence

Deals In Depth: April 2016

Allergan rebounded from the derailed Pfizer acquisition by signing a $3 billion partnership with Heptares to develop small-molecule muscarinic receptor agonists in CNS diseases; there was a huge consolidation in cardiovascular devices through Abbott's $25 billion purchase of St. Jude Medical. Biopharma funding totaled $1.1 billion, while device fundraising reached $248 million.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, February 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014-January 2015.

BioPharmaceutical Medical Device

BioNotebook: Repligen, Pfizer part ways; two deals, six financings

Repligen will not remain a part of Pfizer's "underappreciated" research and development pipeline, since the big pharma has ended its partnership with the Waltham, Massachusetts-based biotechnology company.

Gastrointestinal Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • KemPharm Inc.
  • Senior Management
  • Travis C Mickle, PhD, Pres. & CEO
    R. LaDuane Clifton, CFO
    Christopher Lauderback, PhD, VP, Commercial Ops.
    Sven Guenther, PhD, VP, Res.
    Gordon "Rusty" K Johnson, CBO
    Rene A Braeckman, PhD, VP, Clinical Dev.
  • Contact Info
  • KemPharm Inc.
    Phone: (319) 665-2575
    2656 Crosspark Rd.
    Ste. 100
    Coralville, IA 52241
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register